Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Hervé Tilly, María Gomes da Silva, Umberto Vitolo, et al.
Annals of Oncology (2015) Vol. 26, pp. v116-v125
Open Access | Times Cited: 800

Showing 1-25 of 800 citing articles:

Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump, Sattva S. Neelapu, Umar Farooq, et al.
Blood (2017) Vol. 130, Iss. 16, pp. 1800-1808
Open Access | Times Cited: 1383
Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling, Elı́as Campo, Olivier Hermine, et al.
Annals of Oncology (2017) Vol. 28, pp. iv62-iv71
Open Access | Times Cited: 693
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar, Scott R. Solomon, Jon Arnason, et al.
The Lancet (2022) Vol. 399, Iss. 10343, pp. 2294-2308
Closed Access | Times Cited: 519
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles, Martin Barrett, Robin Foà, et al.
Advances in Therapy (2017) Vol. 34, Iss. 10, pp. 2232-2273
Open Access | Times Cited: 511
Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non–Germinal Center B-Cell Diffuse Large B-Cell Lymphoma
Anas Younes, Laurie H. Sehn, Peter Johnson, et al.
Journal of Clinical Oncology (2019) Vol. 37, Iss. 15, pp. 1285-1295
Open Access | Times Cited: 493
CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP
Norbert Schmitz, Samira Zeynalova, Maike Nickelsen, et al.
Journal of Clinical Oncology (2016) Vol. 34, Iss. 26, pp. 3150-3156
Closed Access | Times Cited: 383
Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy
Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais, et al.
Journal of Clinical Oncology (2014) Vol. 32, Iss. 10, pp. 1066-1073
Open Access | Times Cited: 363
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing
David M. Kurtz, Michael R. Green, Scott V. Bratman, et al.
Blood (2015) Vol. 125, Iss. 24, pp. 3679-3687
Open Access | Times Cited: 304
Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Emanuele Zucca, Luca Arcaini, Christian Buske, et al.
Annals of Oncology (2020) Vol. 31, Iss. 1, pp. 17-29
Open Access | Times Cited: 272
The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance
Emanuele Zucca, Francesco Bertoni
Blood (2016) Vol. 127, Iss. 17, pp. 2082-2092
Open Access | Times Cited: 251
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling, Michele Ghielmini, Simon Rule, et al.
Annals of Oncology (2020) Vol. 32, Iss. 3, pp. 298-308
Open Access | Times Cited: 205
Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study
Jeremy S. Abramson, Scott R. Solomon, Jon Arnason, et al.
Blood (2022) Vol. 141, Iss. 14, pp. 1675-1684
Open Access | Times Cited: 202
Neutrophil Extracellular Traps Induced by IL8 Promote Diffuse Large B-cell Lymphoma Progression via the TLR9 Signaling
Man Nie, Linbin Yang, Xiwen Bi, et al.
Clinical Cancer Research (2018) Vol. 25, Iss. 6, pp. 1867-1879
Open Access | Times Cited: 201
ROBUST: A Phase III Study of Lenalidomide Plus R-CHOP Versus Placebo Plus R-CHOP in Previously Untreated Patients With ABC-Type Diffuse Large B-Cell Lymphoma
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 12, pp. 1317-1328
Open Access | Times Cited: 195
Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
M. Dreyling, Michele Ghielmini, Simon Rule, et al.
Annals of Oncology (2016) Vol. 27, pp. v83-v90
Open Access | Times Cited: 194
Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma
Meng Zhou, Hengqiang Zhao, Wanying Xu, et al.
Molecular Cancer (2017) Vol. 16, Iss. 1
Open Access | Times Cited: 193
Viral Oncology: Molecular Biology and Pathogenesis
Uyen Ngoc Mui, Christopher T. Haley, Stephen K. Tyring
Journal of Clinical Medicine (2017) Vol. 6, Iss. 12, pp. 111-111
Open Access | Times Cited: 188
The landscape of tumor cell states and ecosystems in diffuse large B cell lymphoma
Chloé B. Steen, Bogdan Luca, Mohammad Shahrokh Esfahani, et al.
Cancer Cell (2021) Vol. 39, Iss. 10, pp. 1422-1437.e10
Open Access | Times Cited: 183
Cryoglobulinaemia
Dario Roccatello, David Saadoun, Manuel Ramos‐Casals, et al.
Nature Reviews Disease Primers (2018) Vol. 4, Iss. 1
Closed Access | Times Cited: 173
Randomized Phase II Study of R-CHOP With or Without Bortezomib in Previously Untreated Patients With Non–Germinal Center B-Cell–Like Diffuse Large B-Cell Lymphoma
John P. Leonard, Kathryn S. Kolibaba, James A. Reeves, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 31, pp. 3538-3546
Closed Access | Times Cited: 172
Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma
Anne‐Ségolène Cottereau, Hélène Lanic, Sylvain Mareschal, et al.
Clinical Cancer Research (2016) Vol. 22, Iss. 15, pp. 3801-3809
Open Access | Times Cited: 171
Long-term outcomes from the Phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
Johannes Duell, Kami J. Maddocks, Eva González‐Barca, et al.
Haematologica (2021) Vol. 106, Iss. 9, pp. 2417-2426
Open Access | Times Cited: 110
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Lu Tang, Zhongpei Huang, Heng Mei, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 56
Mosunetuzumab monotherapy is active and tolerable in patients with relapsed/refractory diffuse large B-cell lymphoma
Nancy L. Bartlett, Sarit Assouline, Pratyush Giri, et al.
Blood Advances (2023) Vol. 7, Iss. 17, pp. 4926-4935
Open Access | Times Cited: 43
FDG PET/CT for the detection of bone marrow involvement in diffuse large B-cell lymphoma: systematic review and meta-analysis
Hugo J.A. Adams, Thomas C. Kwee, Bart de Keizer, et al.
European Journal of Nuclear Medicine and Molecular Imaging (2013) Vol. 41, Iss. 3, pp. 565-574
Closed Access | Times Cited: 152
Page 1 - Next Page

Scroll to top